GlobeNewswire·Jul 2, 2026, 8:00 AM ET

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio Limited's affiliate, EG BioMed US Inc., obtained out-of-state clinical laboratory licenses in Rhode Island & Pennsylvania for its CLIA-certified, CAP-accredited lab in Bothell, Washington.
The Rhode Island license covers clinical genetics & was issued May 13, 2026, while the Pennsylvania permit covers clinical chemistry & hematology & was issued June 9, 2026.
These jurisdictions are among the most tightly regulated in the U.S., bringing the laboratory's total operating footprint to 46 states, Washington D.C., & Guam.
The expansion supports early cancer detection operations for pancreatic, colorectal, breast, liver, & other gastrointestinal cancers via blood-based testing services.
YD Bio views this commercial activity as a source of real-world molecular data for validation rather than a standard testing cost-center.
YD Bio entered a non-binding Memorandum of Understanding to merge with EG BioMed in January 2026, with the transaction anticipated to close in 2026 subject to regulatory approvals & definitive agreements.
YD Bio operates as a U.S.-anchored public biotechnology company focusing on DNA methylation-based oncology testing, clinical services, & ocular health commercialization.